The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients

  title={The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients},
  author={Angelique C M Jansen and Emily S. van Aalst-Cohen and Michael W. T. Tanck and Mieke D. Trip and Peter Lansberg and Anho H. Liem and H W O Roeters van Lennep and Eric J.G. Sijbrands and John J Kastelein},
  journal={Journal of Internal Medicine},
Objective.  To determine the contribution of classical risk factors to the development of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolaemia (FH). 

Lipoprotein(a) and cardiovascular disease in heterozygous familial hypercholesterolemia: should we also blame the LDL receptor?

  • R. Santos
  • Biology, Medicine
    Journal of the American College of Cardiology
  • 2014


The review presents current data regarding the etiology and epidemiology of familial hypercholesterolemia, algorithms for identifying patients with FH using clinical scales, genetic testing, cascade screening, and the current tactics of treatment, including in children and pregnant women.

Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis

Elevated lipoprotein(a) (Lp[a]) and familial hypercholesterolemia (FH) are inherited lipid disorders. Their frequencies, coexistence, and associations with premature coronary artery disease (CAD) in

Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia

The association between AVC and both plasma Lp(a) levels and apolipoprotein(a] [apo(a)] kringle IV repeat polymorphisms in asymptomatic statin‐treated patients with heterozygous familial hypercholesterolaemia (FH) is determined.

Drug Therapy of Hypercholesterolaemia in Children and Adolescent

Screening for hypercholesterolaemia in children and adolescents at high risk for premature atherosclerosis between the ages of 2 and 10 years and long-term data on safety, and regular monitoring of those patients treated with statins are still required.

Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

The purpose of this article is to provide an update of clinical and genetic risk factors influencing CVD risk in FH patients, and to discuss future lines of research that could uncover improved methods of treatment for heterozygous FH Patients.

Residual Risk of Cardiovascular Complications in Case of Adequate Lipid-Lowering Therapy

The problems of residual risk of cardiovascu1ar comp1ications deve1opment for high and very high risk patients under adequate lipid-fowering pharmacotherapy in spite of c^lestera! and tow-density 1ipoproteins target level achievement are devoted.

Genetic Determinants of Cardiovascular Disease Risk in Familial Hypercholesterolemia

In a large cohort of FH patients, the G20210A polymorphism in the prothrombin gene is strongly associated with CVD risk and might lead to better risk stratification and hence to more tailored therapy for CVD prevention.

CHAPTER 5 No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with Familial Hypercholesterolemia compared to usual care : results of a randomised controlled trial

This project evaluated the efficacy of an individualised tailored lifestyle intervention on lipids, systolic blood pressure, glucose, body mass index (BMI) and waist circumference in people with FH.

Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.




Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia

Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia and their impact on mortality and morbidity are studied.


Excerpt A large family having familial hypercholesterolemia with a complete pedigree dating from 1732 was studied to define the inheritance, clinical manifestations, and biochemical features. This ...

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

  • Medicine
  • 1991
Familial hypercholesterolaemia is associated with a substantial excess mortality from coronary heart disease in young adults but may not be associated with an additional excess mortality in older patients.

Mortality and Cholesterol Metabolsim in Familial Hypercholesterolemia: Long‐Term Follow‐up of 96 Patients

Assessment of the association of different prognostic factors including parameters of cholesterol metabolism with coronary morbidity and mortality in a study group of 96 patients who were heterozygous for familial hypercholesterolemia indicated that also in subjects without baseline myocardial infarction, low bile acid, cholesterol synthesis, or both predicted increased risk of coronary events.

Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.

There is considerable variation in the severity of cardiovascular disease among patients with familial hypercholesterolemia (FH). Some reports have suggested that plasma lipoprotein(a) [Lp(a)] levels

Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.

Those factors, which, in addition to total cholesterol levels, are associated with the development of premature coronary atherosclerosis in heterozygous FH are identified.